Asymmetric multiscale multifractal analysis (AMMA) of heart rate variability.

Objective.The physiological activity of the heart is controlled and modulated mostly by the parasympathetic and sympathetic nervous systems. Heart rate variability (HRV) analysis is therefore used to observe fluctuations that reflect changes in the activity in these two branches. Knowing that acceleration and deceleration patterns in heart rate fluctuations are asymmetrically distributed, the ability to analyze HRV asymmetry was introduced into MMA.Approach. The new method is called asymmetric multiscale multifractal analysis (AMMA) and the analysis involved six groups: 36 healthy persons, 103 cases with aortic valve stenosis, 36 with hypertrophic cardiomyopathy, 32 with atrial fibrillation, 59 patients with coronary artery disease (CAD) and 13 with congestive heart failure.Main results. Analyzing the results obtained for the 6 groups of patients based on the AMMA method, i.e. comparing the Hurst surfaces for heart rate decelerations and accelerations, it was noticed that these surfaces differ significantly. And the differences occur in most groups for large fluctuations (multifractal parameterq > 0). In addition, a similarity was found for all groups for the AMMA Hurst surface for decelerations to the MMA Hurst surface-heart rate decelerations (lengthening of the RR intervals) appears to be the main factor determining the shape of the complete Hurst surface and so the multifractal properties of HRV. The differences between the groups, especially for CAD, hypertrophic cardiomyopathy and aortic valve stenosis, are more visible if the Hurst surfaces are analyzed separately for accelerations and decelerations.Significance. The AMMA results presented here may provide additional input for HRV analysis and create a new paradigm for future medical screening. Note that the HRV analysis using MMA (without distinguishing accelerations from decelerations) gave satisfactory screening statistics in our previous studies.

Exercise test in patients with asymptomatic aortic stenosis: clinically useful or not?

INTRODUCTION: Aortic valve replacement (AVR) is recommended for symptomatic patients with severe aortic stenosis (AS). In asymptomatic AS (AAS), exercise testing (ET) is recommended; however, it remains controversial. OBJECTIVES: The aim of our study was to assess the importance of ET in patients with AAS. PATIENTS AND METHODS: A total of 89 patients with AAS (53 men; mean [SD] age, 59.5 [11.7] years) underwent 244 symptom­limited ETs. RESULTS: All ETs were clinically negative. During the median (interquartile range) follow­up of 22 (12) months, 39 patients (22 men) developed symptoms (the AVR group). This group was compared with 50 asymptomatic non­AVR patients. In the multivariable Cox analysis, the maximal heart rate during ET less than 85% of age- and sex-adjusted maximal predicted heart rate (THR less than 85%) was related to AVR (P = 0.01). After adjusting for the use of ß­blockers, this was not significant (P = 0.08). In the ß­blocker subgroup, the THR less than 85% was significantly related to AVR in the univariable Cox analysis (hazard ratio, 2.2; 95% CI, 1.07-4.9; P = 0.03) and after adjusting for age (P = 0.047). This relationship was not observed in patients who did not receive ß­blockers. CONCLUSION: In patients with AAS, ET is safe; however, in our study group, the results were not cru­ cial in making a decision to perform AVR. Patients treated with ß­blockers who did not achieve 85% of predicted maximal heart rate had a higher probability of AVR. The influence of the use of ß­blockers on the decision to perform AVR in this patient population warrants further revision.

Heart rate variability, multifractal multiscale patterns and their assessment criteria.

OBJECTIVE: Both the central nervous system and the autonomic nervous system are complex physiological networks which modulate the heart rate. They are spatially extended, have built-in delays and work on many time scales simultaneously-nonhomogeneous networks with multifractal dynamics. The object of our research was the analysis of human heart rate variability (HRV) using the nonlinear multiscale multifractal analysis (MMA) method for several cardiovascular diseases. The analysis of HRV (night-time recordings) involved six groups of patients: 61 healthy persons, 104 cases with aortic valve stenosis, 42 with hypertrophic cardiomyopathy, 36 with atrial fibrillation, 70 patients with coronary artery disease and 19 with congestive heart failure. 85% of patients formed a training data set (282 subjects) and 15% formed a test data set (50 subjects). APPROACH: Multiscale multifractal analysis allows one to analyze the complexity of HRV and find the scaling properties of its fluctuations. The main result of MMA is the Hurst surface, the shape of which changes depending on the medical case analyzed. We prepared six criteria to distinguish a multifractal pattern for healthy subjects. We also prepared additional criteria, enabling one to recognize atrial fibrillation. MAIN RESULTS: For the training data set, we obtained the following accuracy statistics in distinguishing the patients from the healthy: 68% for coronary artery disease, 67% for hypertrophic cardiomyopathy, 88% for atrial fibrillation, 74% for aortic valve stenosis and 83% for congestive heart failure. For the complete training data set we obtained an accuracy of 73%, and 80% for the test data set (mean for ten random selections of the test data set). SIGNIFICANCE: The results of MMA presented here provide an additional input into the diagnostic process and may help to create a paradigm for future studies on medical screening methods, especially in that MMA focuses on very low frequencies of HRV not easily accessible by standard medical techniques. Satisfactory statistics for screening using both MMA and the unfiltered version of LF/HF indicate that the nature of the complete network moderating heart rhythm needs to be studied and that sinus rhythm in clinical patients may not always be separated from arrhythmia when its incidence is large.

Predictors of aortic stenosis severity reclassification using an imaging data fusion method in patients referred for transcatheter aortic valve implantation.

BACKGROUND: The use of imaging data fusion method (IDFM) with multislice computed tomography (MSCT) and two-dimensional transthoracic echocardiography (2D-TTE) in patients with aortic stenosis (AS) may result in reclassification of AS severity from severe to non-severe. AIM: We sought to establish potential predictors of AS severity reclassification using the IDFM method. METHODS: A total of 54 high-risk patients (mean age 79 ± 7.9 years; 40.7% male) with severe AS by 2D-TTE (indexed aortic valve area [AVAi] < 0.6 cm2/m2), referred for transcatheter aortic valve implantation, were included in the analysis. AVAi was subsequently recalculated using IDFM by replacing 2D-TTE left ventricular outflow tract (LVOT) measurements with MSCT LVOT parameters. RESULTS: Imaging data fusion method reclassified 20.4% patients into the potentially non-severe AS group. In a multivariable model including clinical variables, reclassification to non-severe AS by IDFM was independently associated with younger age and diabetes mellitus (DM), (odds ratio [OR] 0.864; 95% confidence interval [CI] 0.76-0.99; p < 0.035 and OR 19.259; 95% CI 2.28-162.41; p < 0.007, respectively). In a multivariable analysis of echocardiographic variables, reclassification was associ-ated with higher LVOT velocity time integral and lower aortic mean gradient (OR 1.402; 95% CI 1.07-1.84; p < 0.014 and OR 0.858; 95%: CI 0.760-0.968; p < 0.013, respectively). In addition, 24.1% of patients were reallocated from low-flow (< 35 mL/m2) to normal-flow AS. CONCLUSIONS: Imaging data fusion method reclassified a substantial proportion of patients with severe AS into a potentially moderate AS group and from a low-flow to a normal-flow AS group. Such regrouping calls for increased diagnostic prudence in AS patients, especially those with specific clinical and echocardiographic predictors of reclassification, such as DM or low aortic mean gradient.

Functional polymorphism of the renalase gene is associated with cardiac hypertrophy in female patients with aortic stenosis.

Renalase decreases circulating catecholamines concentration and is important in maintaining primary cellular metabolism. Renalase acts through the plasma membrane calcium ATPase 4b in the heart, which affects pressure overload but not exercise induced heart hypertrophy. The aim of this study was to test the association between a functional polymorphism Glu37Asp (rs2296545) of the renalase gene and left ventricular hypertrophy in a large cohort of patients with aortic stenosis. The study group consisted of 657 patients with aortic stenosis referred for aortic valve replacement. Preoperative echocardiographic assessment was performed to obtain cardiac phenotypes. Generalized-linear models were implemented to analyze data using crude or full model adjusted for selected clinical factors. In females, the Asp37 variant of the Glu37Asp polymorphism was associated with higher left ventricular mass (p = 0.0021 and p = 0.055 crude and full model respectively), intraventricular septal thickness (p = 0.0003 and p = 0.0143) and posterior wall thickness (p = 0.0005 and p = 0.0219) all indexed to body surface area, as well as relative wall thickness (p = 0.001 and p = 0.0097). No significant associations were found among the male patients. In conclusion, we have found the association of the renalase Glu37Asp polymorphism with left ventricle hypertrophy in large group of females with aortic stenosis. The Glu37Asp polymorphism causes not only amino-acid substitution in FAD binding domain but may also change binding affinity of the hypoxia- and hypertrophy-related transcription factors and influence renalase gene expression. Our data suggest that renalase might play a role in hypertrophic response to pressure overload, but the exact mechanism requires further investigation.

Raised red cell distribution width as a prognostic marker in aortic valve replacement surgery.

BACKGROUND AND AIM: Several studies have reported that elevated red cell distribution width (RDW) is associated with poor outcomes in patients with coronary artery disease, chronic heart failure and aortic stenosis following transcatheter aortic valve replacement. Their prognostic utility in patients undergoing aortic valve replacement (AVR) surgery is unknown. METHODS: We prospectively evaluated the prognostic value of RDW in a group of 191 consecutive patients with severe symptomatic aortic stenosis undergoing AVR. The pre-defined primary endpoint at the 30-day follow-up was composed of: all cause mortality, perioperative myocardial infarction, perioperative renal failure, prolonged mechanical ventilation, stroke, heart failure, successfully resuscitated cardiac arrest, the occurrence of multiple-organ failure, and the need for additional surgery for any reason. The secondary endpoint was total mortality. RESULTS: The composite endpoint occurred in 54 patients. In univariate analysis RDW (p < 0.0001), haemoglobin level (p = 0.005), haematocrit (p = 0.01), red blood cell count (RBC; p = 0.002), glomerular filtration rate (p = 0.003), New York Heart Association classification (p = 0.02), atrial fibrillation (p = 0.0044), and pulmonary blood pressure (p = 0.004) were associated with the occurrence of the composite endpoint. RDW (p = 0.0005), haemoglobin level (p = 0.004), haematocrit (p = 0.004), RBC (p = 0.0009) and mean corpuscular volume (p = 0.01) were associated with an increased risk of death. In multivariate analysis, RDW (OR 3.274; 95% CI 1.285-8.344; p = 0.0003) and RBC (OR 0.373; 95% CI 0.176-0.787; p = 0.0097) remained independent predictors of the composite endpoint. Receiver operating characteristic analysis determined a cut-off value of RDW for the prediction of the occurrence of the combined endpoint at 14.1%. CONCLUSIONS: Elevated RDW is associated with a worse outcome following AVR, independent of RBC.

Aortic valve calcification in 499 consecutive patients referred for computed tomography.

INTRODUCTION: Aortic valve calcification (AVC) is the most common cause of aortic stenosis. The aim of the study was to assess the prevalence of aortic valve, coronary artery and aortic calcifications and to evaluate the correlation between calcification of the aortic valve, coronary arteries and aorta. MATERIAL AND METHODS: The study included 499 patients aged 60 years and over who underwent coronary computed tomography because of chest pain. Beside coronary artery calcium score (CAC), we evaluated AVC and ascending aorta calcifications (AAC). RESULTS: Aortic valve calcification was found in 144 subjects (28.9% of the whole study population). Prevalence of CAC and AAC was higher than AVC and amounted to 73.8% and 54.0%. Prevalence of AVC, CAC and AAC was significantly lower in the group of patients ≤ 70 years than in the group of patients > 70 years of age (p = 0.0002, p < 0.0001, p < 0.0001). Aortic valve calcification was more often observed in men than women (34.7% vs. 25.4%, p = 0.02). Degree of aortic valve calcification was also significantly higher among men than women (median score 4 vs. 0, p = 0.01). Similar observations were true for CAC and AAC, where both prevalence and degree of calcification was higher among men than women. In the whole study population no correlation was noted between AVC and CAC or AAC (p = 0.34, p = 0.85). There was a significant correlation between AAC and CAC (p < 0.0001). CONCLUSIONS: Despite some similarities in pathological mechanism and risk factors, a degenerative defect of the aortic valve could be independent of atheromatous lesions in the coronary arteries and aorta.

The impact of transcatheter aortic valve implantation on left ventricular performance and wall thickness - single-centre experience.

INTRODUCTION: Transcatheter aortic valve implantation (TAVI) is a treatment alternative for the elderly population with severe symptomatic aortic stenosis (AS) at high risk for surgical aortic valve replacement (SAVR). AIM: To assess the impact of TAVI on echocardiographic parameters of left ventricular (LV) performance and wall thickness in patients subjected to the procedure in a single-centre between 2009 and 2013. MATERIAL AND METHODS: The initial group consisted of 170 consecutive patients with severe AS unsuitable for SAVR. Logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE) was 21.73 ±12.42% and mean age was 79.9 ±7.5 years. RESULTS: The TAVI was performed in 167 (98.2%) patients. Mean aortic gradient decreased significantly more rapidly after the procedure (from 58.6 ±16.7 mm Hg to 11.9 ±4.9 mm Hg, p < 0.001). The LV ejection fraction (LVEF) significantly increased in both short-term and long-term follow-up (57 ±14% vs. 59 ±13%, p < 0.001 and 56 ±14% vs. 60 ±12%, p < 0.001, respectively). Significant regression of interventricular septum diameter at end-diastole (IVSDD) and end-diastolic posterior wall thickness (EDPWth) was noted in early (15.0 ±2.4 mm vs. 14.5 ±2.3 mm, p < 0.001 and 12.7 ±2.1 mm vs. 12.4 ±1.9 mm, p < 0.028, respectively) and late post-TAVI period (15.1 ±2.5 mm to 14.3 ±2.5 mm, p < 0.001 and 12.8 ±2.0 mm to 12.4 ±1.9 mm, p < 0.007, respectively). Significant paravalvular leak (PL) was noted in 21 (13.1%) patients immediately after TAVI and in 13 (9.6%) patients in follow-up (p < 0.001). Moderate or severe mitral regurgitation (msMR) was seen in 24 (14.9%) patients from the initial group and in 19 (11.8%) patients after TAVI (p < 0.001). CONCLUSIONS: The TAVI had an immediate beneficial effect on LVEF, LV walls thickness, and the incidence of msMR. The results of the procedure are comparable with those described in other centres.

Association of the common genetic polymorphisms and haplotypes of the chymase gene with left ventricular mass in male patients with symptomatic aortic stenosis.

We investigated the association between polymorphisms and haplotypes of the chymase 1 gene (CMA1) and the left ventricular mass index (LVM/BSA) in a large cohort of patients with aortic stenosis (AS). Additionally, the gender differences in cardiac remodeling and hypertrophy were analyzed. The genetic background may affect the myocardial response to pressure overload. In human cardiac tissue, CMA1 is involved in angiotensin II production and TGF-ß activation, which are two major players in the pathogenesis of hypertrophy and fibrosis. Preoperative echocardiographic data from 648 patients with significant symptomatic AS were used. The LVM/BSA was significantly lower (p<0.0001), but relative wall thickness (RWT) was significantly higher (p = 0.0009) in the women compared with the men. The haplotypes were reconstructed using six genotyped polymorphisms: rs5248, rs4519248, rs1956932, rs17184822, rs1956923, and rs1800875. The haplotype h1.ACAGGA was associated with higher LVM/BSA (p = 9.84 × 10(-5)), and the haplotype h2.ATAGAG was associated with lower LVM/BSA (p = 0.0061) in men, and no significant differences were found in women. Two polymorphisms within the promoter region of the CMA1 gene, namely rs1800875 (p = 0.0067) and rs1956923 (p = 0.0015), influenced the value of the LVM/BSA in males. The polymorphisms and haplotypes of the CMA1 locus are associated with cardiac hypertrophy in male patients with symptomatic AS. Appropriate methods for the indexation of heart dimensions revealed substantial sex-related differences in the myocardial response to pressure overload.

Incidence of syncope and cardiac arrest in patients with severe aortic stenosis.

INTRODUCTION:  Syncope and sudden cardiac arrest are known complications of aortic stenosis (AS). OBJECTIVES:  The aim of the study was to investigate the incidence of these complications in patients with severe symptomatic AS and to analyze whether basic clinical data and electrocardiographic (ECG) and echocardiographic parameters can be the markers of these complications. PATIENTS AND METHODS:  The incidence of syncope and sudden cardiac arrest and its correlations with clinical and diagnostic data (ECG, echocardiography, Holter monitoring) were analyzed in 514 patients (mean age, 60 ±11 y) with severe symptomatic AS before valve replacement. RESULTS:  Syncope was reported in 167 patients (32%), and aborted cardiac arrest in 14 (2.7%; ventricular fibrillation, 13 patients; third-degree atrioventricular block, 1 patient). None of the analyzed parameters was related to syncope. Patients with a history of sudden cardiac arrest had higher New York Heart Association class (P = 0.01), more frequent history of syncope (P = 0.017), higher left ventricular mass index (P = 0.02), lower ejection fraction (P = 0.004), longer QRS duration (P = 0.048), corrected QT (P = 0.002), QT dispersion (P = 0.007), and a higher number of ventricular arrhythmias in 24-hour Holter monitoring (P = 0.002). A multivariate analysis showed correlations between syncope, ejection fraction of less than 45%, and QTd exceeding 60 ms and aborted cardiac arrest. At least 2 of these parameters were observed in 8 of 14 patients (P <0.001): sensitivity, 57%; specificity, 86%; positive predictive value, 10%; and negative predictive value, 98%. CONCLUSIONS:  The incidence of sudden cardiac arrest in severe symptomatic AS is low. It is higher in patients with a history of syncope, prolongation of QTd, and reduced ejection fraction. None of the clinical and diagnostic parameters were associated with a history of syncope in patients with AS.

Hypertension in aortic stenosis: more questions than answers.

Although hypertension and aortic stenosis are the most common cardiovascular diseases, the impact of hypertension on the natural history of aortic stenosis, the structure and function of the left ventricle, the assessment of valve defect severity and its progression are not fully understood. Hypertension not only can modify the exploratory findings of aortic stenosis, but may also interfere with the assessment of severity, and even have an impact on patients outcome. In the absence of specific cohort studies, the nature of the association between aortic stenosis and high blood pressure is not clear and the published results are often contradictory. Unknown is the true frequency of both conditions, the rules of diagnosis and the treatment itself.

Antithrombotic therapy - predictor of early and long-term bleeding complications after transcatheter aortic valve implantation.

INTRODUCTION: Dual antiplatelet therapy (DAPT) - aspirin and clopidogrel - is recommended after transcatheter aortic valve implantation (TAVI) without an evidence base. The main aim of the study was to estimate the impact of antithrombotic therapy on early and late bleeding. Moreover, we assessed the impact of patients' characteristics on early bleeding and the influence of bleeding on prognosis. MATERIAL AND METHODS: Between 2009 and 2011, 83 consecutive TAVI patients, age 81.1 ±7.2 years, were included. Bleeding complications were defined by the Valve Academic Research Consortium (VARC) scale. The median follow-up was 12 ±15.5 months (range: 1 to 23) and included 68 (81.9%) patients. RESULTS: Early bleeding occurred in 51 (61.4%) patients. Vitamin K antagonists (VKA) pre-TAVI (p = 0.001) and VKA + clopidogrel early post-TAVI (p = 0.04) were the safest therapies; in comparison to the safest one, peri-procedural DAPT (p = 0.002; p = 0.05) or triple anticoagulant therapy (TAT) (p = 0.003, p = 0.05) increased the risk for early bleeding. Predictors for early bleeding were: clopidogrel pre-TAVI (OR: 4.43, 95% CI: 1.02-19.24, p = 0.04), preceding percutaneous coronary intervention (PCI) (10.08, OR: 95% CI: 1.12-90.56, p = 0.04), anemia (OR: 4.00, 95% CI: 1.32-12.15, p = 0.01), age > 85 years (OR: 5.96, 95% CI: 1.47-24.13, p = 0.01), body mass index (BMI) (OR: 0.86, 95% CI: 0.74-0.99, p = 0.04). Late bleeding occurred in 35 patients (51.4%) on combined therapy, and none on VKA or clopidogrel monotherapy (p = 0.04). Bleeding complications did not worsen the survival. CONCLUSIONS: This study seems to suggest that advanced age, BMI, and a history of anemia increased the risk for early bleeding after TAVI. Clopidogrel pre-TAVI should be avoided; therefore, time of preceding PCI should take into account discontinuation of clopidogrel in the pre-TAVI period. Vitamin K antagonists with clopidogrel seems to be the safest therapy in the early post-TAVI period, similarly as VKA/clopidogrel monotherapy in long-term prophylaxis.

Factors affecting long-term survival after aortic valve replacement.

BACKGROUND AND AIM: To evaluate long-term outcomes of surgical aortic valve replacement (AVR) due to significant aortic stenosis (AS) and assess changes in factors affecting survival during a 10-year period in patients referred for surgery from a single centre. METHODS: We evaluated 1143 patients (478 women, 665 men; mean age 61 ± 5 years) treated in the Department of Valvular Heart Disease at the Institute of Cardiology in Warsaw who were referred for AVR due to significant AS in 1998-2008 and survived the surgery and the initial 30-day postoperative period. We assessed long-term survival in relation to preoperative parameters including demographic data (age, gender), clinical variables (New York Heart Association [NYHA] class, presence of a significant coronary artery stenosis, arterial hypertension, reduced left ventricular ejection fraction [LVEF]), and operative parameters (prosthetic valve type: biological vs. mechanical, and the type of the surgery: isolated AVR vs. AVR combined with coronary artery bypass grafting). RESULTS: Ten-year survival was worse in men compared to women (p = 0.001), with the effect of gender gradually decreasing after 3 years of follow-up. Factors affecting long-term survival included age (p = 0.0001) and NYHA class (p = 0.005) in women, and age (p = 0.0001), NYHA class (p = 0.0001), arterial hypertension (p = 0.01), reduced LVEF (p = 0.03), and the presence of significant coronary artery stenoses (p = 0.0001) in men. Evaluation of factors affecting 1-, 3-, 5-, and 7-year survival showed their variability mostly in men. CONCLUSIONS: Long-term surgical outcomes in patients with significant AS are very good, with better survival in women compared to men, although these differences attenuated after 3 years. Factors affecting 10-year survival are different in women and men: a significant effect in women was noted only for age and preoperative NYHA class, while in men for age, NYHA class, hypertension, reduced LVEF, and the presence of significant coronary artery stenoses. During 10-year follow-up, longitudinal changes can be noted in factors affecting survival after AVR.

May dual-source computed tomography angiography replace invasive coronary angiography in the evaluation of patients referred for valvular disease surgery?

BACKGROUND: Coronary computed tomography (CT) angiography is currently the only alternative to invasive angiography in the evaluation of coronary anatomy. In patients referred for valvular or thoracic aortic disease surgery, invasive coronary angiography remains the gold standard required by cardiac surgeons during the preoperative evaluation. According to the current European Society of Cardiology guidelines, evaluation of coronary anatomy is recommended in all patients above 40 years of age, with a history of coronary artery disease (CAD), in postmenopausal women, patients with left ventricular systolic dysfunction, with suspected ischaemic aetiology of mitral regurgitation, and in patients with one or more risk factors for CAD. The possibility to perform coronary CT angiography to exclude CAD before planned non-coronary cardiac surgery was first allowed in the 2010 Report of the American College of Cardiology Foundation Task Force on Expert Consensus. AIM: To evaluate the usefulness of dual-source CT for the evaluation of coronary anatomy in patients before planned cardiac valvular surgery. METHODS: We studied 98 consecutive patients with a haemodynamically significant valvular heart disease and guideline-based indications for coronary angiography to exclude CAD before planned valvular surgery. Exclusion criteria included cardiac arrhythmia (atrial fibrillation, frequent ventricular and supraventricular premature beats), estimated glomerular filtration rate < 60 mL/min/1.73 m(2), allergy to iodine contrast agents, and lack of patient consent. Mean patient age was 58.8 (range 30-78) years. Coronary artery calcium score (CACS) was first determined in all patients. Coronary CT angiography was not performed if CACS was > 1000. In the remaining patients, complete CT evaluation was performed with the administration of a contrast agent. Conventional invasive coronary angiography was subsequently performed in patients with at least one > 50% stenosis, artifacts due to calcifications, or motion artifacts. RESULTS: In 79 (80.6%) patients, CT angiography excluded the presence of a significant coronary artery stenosis without the need for invasive angiography. Conventional coronary angiography was required in 19 (19.4%) patients, including 13 (13.3%) patients with a > 50% stenosis in CT angiography, 2 (2%) patients with calcification artifacts, 1 (1%) patient with motion artifacts, 2 (2%) patients with CACS > 1000 in whom CT angiography was nor performed, and 1 (1%) patient with allergic symptoms during administration of a test dose of the contrast agent. Ultimately, significant CAD was diagnosed in 9 (9.2%) patients in whom coronary artery bypass surgery was also performed. In addition, vascular anomalies were diagnosed with cardiac CT angiography in 5 (5.1%) patients. In 14 patients, CT angiography was also used for previously planned evaluation of a coexisting aortic aneurysm. CONCLUSIONS: Coronary CT angiography may be useful to exclude significant CAD in patients referred for valvular disease surgery.

[Conduction disturbances and permanent cardiac pacing after transcatheter implantation of the CoreValve aortic bioprosthesis: initial single centre experience].

BACKGROUND: The rate of significant conduction disturbances requiring permanent pacemaker implantation (PPI) following surgical aortic valve replacement (AVR) is 2-8%. Transcatheter aortic valve implantation (TAVI) is an alternative management approach in patients with severe aortic stenosis who are not considered candidates for AVR. The TAVI using the CoreValve (CV) bioprosthesis is associated with a nearly 30% rate of conduction disturbances requiring postprocedural PPI. AIM: To provide an initial evaluation of the rate of conduction disturbances and the need for PPI, and to analyse factors that increase the risk of this complication in patients undergoing TAVI using CV bioprosthesis. In addition, we evaluated the rate of permanent conduction disturbances in patients who underwent PPI at one year after TAVI. METHODS: We studies 22 initial patients in a single centre who underwent CV bioprosthesis implantation in 2009-2010. After exclusion of 6 patients with preprocedural PPI, we ultimately evaluated 16 patients. Uni- and multivariate analyses were performed using χ(2), Fisher, and Wilcoxon tests, and logistic regression analysis was performed using the SAS software. RESULTS: Overall, 8 (50%) patients in our study group required PPI after TAVI (TAVI + PPI), and the remaining 8 patients did not require PPI (TAVI). The most common indication for PPI was complete heart block. The decision to implant a pacemaker was made on average at 9 ± 7 days following TAVI (range 3 to 22 days). When we analysed risk factors for PPI that were unrelated to the TAVI procedure, we found that the TAVI + PPI group was characterised (vs the TAVI group) by a significantly larger diameter of the native aortic valve (p = 0.03) and a larger left ventricular outflow tract (LVOT) dimension in the frontal (p = 0.02) and the corresponding frontal dimension in the transverse view (p = 0.01) by computed tomography angiography. Logistic regression analysis showed that the risk of PPI increased more than 2.5 times for each increase in the aortic annulus diameter by 1 mm (OR 2.64; 95% CI 0.90-7.74). None of the risk factors related to TAVI resulted in a significant increase in the rate of PPI. Among the patients who underwent PPI, we only noted a trend for a larger valvulotomy balloon diameter (p = 0.08), shorter procedure duration (p = 0.06), and deeper CV insertion within LVOT (p = 0.09). In addition, the bioprosthesis was inserted deeper in those patients who developed new LBBB after TAVI (p = 0.06). The ECG analysis at one day after the procedure showed a significant prolongation of PR, QRS, QT, and QTc intervals, and increased left axis deviation in the TAVI + + PPI group. In addition, the TAVI + PPI group showed increased QRS duration (p = 0.03) and increased left axis deviation (p = 0.049) compared to the TAVI group. Each increase in QRS duration by 10 ms was associated with 2.5-fold increase in the risk of PPI (OR 1.10; 95% CI 0.97-1.22), and each increase in PR interval duration by 10 ms with a 23% increase in risk (OR 1.02; 95% CI 0.99-1.05). New LBBB following CV implantation was noted significantly more frequently in the TAVI + PPI group vs the TAVI group (p 〈 0.0003). Pacemaker interrogation at one year after TAVI showed that the mean percentage of ventricular pacing in all patients with a pacemaker (DDD and VVI) pacing was 41%, and it was less than 10% in 2 patients. CONCLUSIONS: 1. Transcatheter implantation of a CV bioprosthesis is associated with an increased risk of persistent conduction disturbances and subsequent PPI. 2. New LBBB after TAVI may predict the need for PPI. 3. Careful ECG monitoring is necessary for one week after CV bioprosthesis implantation due to a risk of atrioventricular conduction disturbances and the need for PPI. 4. Patients at an increased risk of postprocedural PPI may be those with deep bioprosthesis insertion in LVOT, larger LVOT diameter, and larger aortic annulus diameter in the frontal view. These observations require confirmation in a larger group of patients.

[Coarctation of aorta in a 40 year-old female with bicuspid aortic valve - a case report]. / Koarktacja aorty u 40−letniej chorej z dwuplatkowa zastawka aortalna. Wartosc logicznego myslenia. Czy warto dobrze zbadac chorego prostymi metodami czy od razu jako pierwsze zlecac badania specjalistyczne?

Patients with bicuspid aortic valve quite often have another abnormalities of cardiovascular system. In the paper we present diagnostic difficulties in 40 year-old woman with bicuspid aortic valve and coarctation of aorta.

Transapical aortic valve implantation - a rescue procedure for patients with aortic stenosis and "porcelain aorta".

Surgical aortic valve replacement (AVR) still remains the treatment of choice in symptomatic significant aortic stenosis (AS). Due to technical problems, extensive calcification of the ascending aorta ("porcelain aorta") is an additional risk factor for surgery and transapical aortic valve implantation (TAAVI) is likely to be the only rescue procedure for this group of patients. We describe the case of an 81-year-old woman with severe AS and "porcelain aorta", in whom the only available life-saving intervention was TAAVI.

Refined multiscale entropy: application to 24-h Holter recordings of heart period variability in healthy and aortic stenosis subjects.

Multiscale entropy (MSE) was proposed to characterize complexity as a function of the time-scale factor tau. Despite its broad use, this technique suffers from two limitations: 1) the artificial MSE reduction due to the coarse graining procedure and 2) the introduction of spurious MSE oscillations due to the suboptimal procedure for the elimination of the fast temporal scales. We propose a refined MSE (RMSE), and we apply it to simulations and to 24-h Holter recordings of heart rate variability (HRV) obtained from healthy and aortic stenosis (AS) groups. The study showed that the refinement relevant to the elimination of the fast temporal scales was more helpful at short scales (spanning the range of short-term HRV oscillations), while that relevant to the procedure of coarse graining was more useful at large scales. In healthy subjects, during daytime, RMSE was smaller at short scales (i.e., tau = 1-2) and larger at longer scales (i.e., tau = 4-20) than during nighttime. In AS population, RMSE was smaller during daytime both at short and long time scales (i.e., tau = 1 -11) than during nighttime. RMSE was larger in healthy group than in AS population during both daytime (i.e., tau = 2 -9) and nighttime (i.e., tau = 2). RMSE overcomes two limitations of MSE and confirms the complementary information that can be derived by observing complexity as a function of the temporal scale.

Brain natriuretic peptide as a marker of left ventricular hypertrophy in patients with aortic stenosis.

BACKGROUND AND AIM OF THE STUDY: In aortic stenosis (AS), serum levels of brain natriuretic peptide (BNP) are elevated, but the relation of this elevation to the degree of left ventricular hypertrophy (LVH) remains unclear. The study aim was to assess the relationship between BNP and LVH (expressed as LV mass index, LVMI) and LV wall thickness index (WThI) in a group of patients. METHODS: A total of 147 patients with AS (85 men, 62 women; mean age 61 +/- 12 years) each underwent echocardiography and serum BNP analysis. The correlation between serum BNP level and LVH was investigated, with patient gender, age, NYHA class, AS severity and presence of coronary artery disease also being taken into account. RESULTS: Among AS patients, serum BNP levels ranged from 3 to 2010 pg/ml; mean BNP levels were similar in women and men (213 +/- 302 and 253 +/- 375 pg/ml, respectively). The BNP level also correlated directly with the LVMI (r = 0.55; p <0.0001), WThI (r = 0.26; p <0.001), end-diastolic dimension (r = 0.43; p <0.0001), mean aortic gradient (r = 0.25; p = 0.002), age (r = 0.27; p = 0.001); and correlated inversely with the LV ejection fraction (r = -0.52; p <0.0001). Eccentric LVH was associated with a significantly higher serum BNP level (506 +/- 558 pg/ml) than concentric-type hypertrophy (190 +/- 254 pg/ml; p = 0.002). CONCLUSION: The measurement of serum BNP levels is of potential value when monitoring LVH in aortic stenosis patients.